ProCE Banner Activity

SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers

Conference Coverage

The phase III SWOG 1815 trial showed that adding nab-paclitaxel to first-line gemcitabine/cisplatin did not significantly prolong OS or PFS and was associated with increased severe hematologic toxicity in advanced biliary tract cancers.

Released: January 26, 2023

Expiration: January 25, 2024

No longer available for credit.


Provided by

ProCE Banner


Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.